Firm Analyst
Benchmark Robert Wasserman
Berenberg Capital Markets Anita Dushyanth, Ph.D.
BMO Capital Markets Matthew Luchini
Canaccord Genuity Arlinda Lee, Ph.D.
Cantor Charles Duncan, Ph.D.
Evercore ISI Michael DiFiore, Pharm.D., MBA
Goldman Sachs Graig C. Suvannavejh, Ph.D.
Jefferies & Company Eun K. Yang, Ph.D.
JMP Securities Jason N. Butler, Ph.D.
JP Morgan Jessica Fye
Piper Sandler Joseph Catanzaro
SVB Leerink Geoffrey C. Porges MBBS
Wells Fargo Nick Abbott, Ph.D.

Halozyme Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Halozyme Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Halozyme Therapeutics, Inc. or its management. Halozyme Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.


Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok